Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;91(5):774-6.
doi: 10.1038/clpt.2012.21.

Clopidogrel: a case for indication-specific pharmacogenetics

J A Johnson  1 , D M Roden, L J Lesko, E Ashley, T E Klein, A R Shuldiner
Affiliations

Clopidogrel: a case for indication-specific pharmacogenetics

J A Johnson et al. Clin Pharmacol Ther. 2012 May.

Abstract

The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

J.A.J., D.M.R., T.E.K., and A.R.S. are funded by the NIH Pharmacogenomics Research Network (PGRN). J.A.J. and A.R.S. have NIH funding for clopidogrel pharmacogenomics research, and A.R.S. is a consultant for United States Diagnostics, Inc. L.J.L. was the Director of the Office of Clinical Pharmacology at the FDA at the time the clopidogrel boxed warning was issued. E.A. is founder, stakeholder, and equity owner of Personalis, Inc. D.M.R. has received funds for consulting activity from Merck, Novartis, Astellas, and Sanofi-Aventis and receives royalty payments on a patent for predicting drug-induced arrhythmia.

References

    1. Hulot JS, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244–2247. - PubMed
    1. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306:2704–2714. - PubMed
    1. Mega JL, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362. - PubMed
    1. Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328–332. - PMC - PubMed
    1. Shuldiner AR, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–857. - PMC - PubMed

Publication types